Mohamed Ashraf Osman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mohamed Ashraf Osman has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Muhammad Meeran Saleem
Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan
1 shared publication - Shamat Fathi Shamat
Faculty of Medicine, National Ribat University, Khartoum, Sudan
1 shared publication - Usaid Ahmed
Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan
1 shared publication
Latest Publications
- Open Access
- 18 December 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (2) , 923-925
Novel FDA-approved zavegepant drug for treating migraine
Migraine is a complex neurological disorder characterized by recurring episodes of severe headaches. The pathophysiology of migraine involves abnormalities in neuronal networks, cortical spreading depression, and sensitization of trigeminovascular pathways. The global prevalence of migraine has increased substantially, warranting advancements in treatment strategies. A significant trigger in migraine pathophysiology is calcitonin gene-related peptide (CGRP). Several drugs, such as gepants and monoclonal antibodies (MABs) targeting CGRP or its receptor, have been developed to antagonize CGRP signaling. Zavegepant (Zavzpret), a novel CGRP receptor antagonist, has recently been approved by the FDA for the acute treatment of migraine. Clinical trials have demonstrated its efficacy in providing headache and symptom relief, with a statistically significant percentage of patients achieving freedom from headaches and most bothersome symptoms. Despite mild adverse effects, such as taste disorders and nausea, Zavzpret’s overall safety profile remains acceptable.
- 18 December 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (2) , 923-925
Open AccessNovel FDA-approved zavegepant drug for treating migraine
Migraine is a complex neurological disorder characterized by recurring episodes of severe headaches. The pathophysiology of migraine involves abnormalities in neuronal networks, cortical spreading depression, and sensitization of trigeminovascular pathways. The global prevalence of migraine has increased substantially, warranting advancements in treatment strategies. A significant trigger in migraine pathophysiology is calcitonin gene-related peptide (CGRP). Several drugs, such as gepants and monoclonal antibodies (MABs) targeting CGRP or its receptor, have been developed to antagonize CGRP signaling. Zavegepant (Zavzpret), a novel CGRP receptor antagonist, has recently been approved by the FDA for the acute treatment of migraine. Clinical trials have demonstrated its efficacy in providing headache and symptom relief, with a statistically significant percentage of patients achieving freedom from headaches and most bothersome symptoms. Despite mild adverse effects, such as taste disorders and nausea, Zavzpret’s overall safety profile remains acceptable.